RIFABUTIN (UNII: 1W306TDA6S) (RIFABUTIN - UNII:1W306TDA6S) - αποτελεσματα

pfizer new zealand limited - rifabutin 150mg - capsule - 150 mg - active: rifabutin 150mg - mycobutin is indicated for infections caused by mycobacteria, such as m. tuberculosis, m. avium intracellulare complex (mac) and other atypical mycobacteria. in infections caused by mac and other atypical mycobacteria such as m. xenopi, mycobutin has been shown to be effective for the treatment of both disseminated and localised disease, also in immunocompromised hiv positive patients. mycobutin is also indicated for the prophylaxis of m. avium intracellulare complex (mac) infections in immunodepressed patients with cd4 counts lower than or equal to 100/ml. in the treatment of tubercular disease, mycobutin has been shown to be effective for the treatment of patients with chronic pulmonary tuberculosis, even if caused by multidrug-resistant m. tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin therapy should always be given in combination with other antimycobacterial drugs not belonging to the family of rifamycins.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

mycobutin 150mg hard capsules

pfizer healthcare ireland - rifabutin - capsule, hard - 150 milligram(s) - antibiotics; rifabutin

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mycobutin 150 mg hard caps.

pfizer sa-nv - rifabutin 150 mg - capsule, hard - 150 mg - rifabutin 150 mg - rifabutin

Καναδάς - Αγγλικά - Health Canada

mycobutin capsule

pfizer canada ulc - rifabutin - capsule - 150mg - rifabutin 150mg - antituberculosis agents